STEINER DAVID P
Known title: DirectorCIK: 0001197040
Associated companies
Transaction History
| FDX | ▲ Buy | Grant | 755 | $0 | 9/23/2024 | View on chart |
| FDX | ▲ Buy | Grant | 542 | $140K | 9/23/2024 | View on chart |
| FDX | ▲ Buy | Option Exercise | 2,535 | $407K | 7/2/2024 | View on chart |
| FDX | ▼ Sell | Open Market | 1,369 | $408K | 7/2/2024 | View on chart |
| FDX | ▲ Buy | Grant | 745 | $0 | 9/22/2023 | View on chart |
| FDX | ▲ Buy | Grant | 534 | $140K | 9/22/2023 | View on chart |
| FDX | ▲ Buy | Option Exercise | 3,700 | $426K | 4/10/2023 | View on chart |
| FDX | ▼ Sell | Open Market | 1,856 | $430K | 4/10/2023 | View on chart |
| FDX | ▲ Buy | Grant | 954 | $140K | 9/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
FedEx eyes record-high Q4 delivery prices and expands digital pharma booking
FedEx expects delivery rates to reach record highs in the fourth quarter, according to a TD Cowen/AFS note. The company says its recent freight‑spin strategy has improved performance, though pricing is still relatively high. It also launched a digital booking platform for European cold‑chain pharmaceutical shipments to make the process smoother for customers.
FedEx eyes record-high Q4 delivery prices and expands digital pharma booking. FedEx expects delivery rates to reach record highs in the fourth quarter, according to a TD Cowen/AFS note. The company says its recent freight‑spin strategy has improved performance, though pricing is still relatively high. It also launched a digital booking platform for European cold‑chain pharmaceutical shipments to make the process smoother for customers.